ArticleBMC cancer2026
Clinical outcomes of percutaneous cryoablation for pulmonary metastases of soft tissue and bone sarcomas under local anesthesia: a single-institution retrospective cohort study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe management of pulmonary metastases of soft tissue and bone sarcomas is challenging due to their resistance to chemotherapy and radiotherapy. This study aimed to evaluate local tumor progression, overall survival (OS), and procedural safety after percutaneous cryoablation for pulmonary metastases of soft tissue and bone sarcomas.
methodsThis retrospective cohort study included 28 patients who underwent percutaneous cryoablation for 84 metastatic lung tumors of soft tissue and bone sarcomas during 53 sessions between July 2002 and December 2016. Percutaneous cryoablation was performed under local anesthesia using the CRYOcare system and computed tomography fluoroscopy. Procedural complications within 30 days were assessed using prospectively recorded clinical data and retrospectively graded according to the Common Terminology Criteria for Adverse Events version 5.0. The time to local progression of the treated tumors and overall survival were estimated using the Kaplan-Meier method.
resultsAll cryoablation procedures were performed under local anesthesia. The median tumor diameter was 1.1 cm (range: 0.4-6.5 cm). Twelve tumors (14.3%) showed local tumor progression after initial cryoablation during the median follow-up duration of 16 months (range: 0-216 months). The primary efficacy rates were 88.8%, 79.1%, and 79.1% at 1, 3, and 5 years, respectively. After repeat cryoablation for four tumors with local progression, the assisted efficacy rates were 95.6%, 82.8%, and 77.9% at 1, 3, and 5 years, respectively. Three tumors in two patients had no local progression for more than 10 years. A tumor diameter of ≤ 2 cm was significantly associated with improved primary and assisted efficacy rates (P = 0.024 and P = 0.015, respectively). The median OS was 34 months (range, 2-155 months), and the OS rates were 75.0%, 52.8%, and 28.8% at 1, 3, and 5 years, respectively. Adverse events occurred in 31 sessions (58.5%); all were grade 1 or 2, and no grade ≥ 3 adverse events or 30-day mortality were observed.
conclusionsIn this selected single-institution cohort of nonsurgical candidates with pulmonary metastases of soft tissue and bone sarcomas, percutaneous cryoablation was feasible and was associated with local tumor control and an acceptable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.